Special Issue "Drug Discovery of Antiprotozoal Agents"
Deadline for manuscript submissions: closed (25 October 2023) | Viewed by 10536
Interests: drug design; neglected diseases; antimicrobial; anti-cancer
Special Issues, Collections and Topics in MDPI journals
Protozoan diseases continue to be a serious worldwide health problem, causing serious social and economic impacts, especially in developing countries. Protozooses such as malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, trichomoniasis, giardiasis and amoebiasis are responsible for high mortality and morbidity rates, with the potential to affect more than 1 billion people worldwide.
Globally, the endemicity of these diseases has increased due to several factors, including: low investment in research in the search for new drugs with novel mechanisms of action; lack of effective drugs with low adverse effects and low toxicity, as well as to the increase in drug resistance, the increasing appearance of cross resistance, which has made the few therapeutic options ineffective in many cases.
This problem has led many researchers to seek new antiprotozoal drugs, through different scientific approaches, based mainly on two axes: 1) isolation and identification of drug candidates through bioprospection of natural resources (plants, animals, microorganisms); 2) drug design based on the use of medicinal chemistry tools, involving synthetic chemistry procedures, associated or not with computational approaches (structure-based drug discovery and ligand-based drug discovery)
In this special Issue, authors are invited to submit review and original articles related to the recent research in drug design and discovery, synthesis, and pharmacological properties (in vitro and in vivo) of natural products and/or synthetic compounds that have the potential to become drug candidates for protozoan diseases. As well as presenting the latest advances in the search for pharmacological targets for protozoan diseases, with the aim to provide researchers with the most up-to-date information in this field.
Potential topics include but are not limited to:
- Bioprospecting of natural products;
- Drug Design & Discovery;
- Computational methods (ADMET, CADD, LBDD, SBDD, QSAR, VS);
- In vitro, and in vivo evaluations;
- Recent advances in antiprotozoal drugs;
Prof. Dr. Francisco Jaime Bezerra Mendonça Júnior
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antiprotozoal agents
- drug discovery
- medicinal chemistry
- natural products
- in vitro and in vivo studies
- computer-aided drug design
- molecular docking
- virtual screening